Therapeutic albumin binding to remove amyloid-β

Journal of Alzheimer's Disease

Volumn 29, Issue 1, 2012, Pages 159-170

  Costa, Montserrat ^a   Ortiz, Ana M ^a   Jorquera, Juan I ^a  

^a Instituto Grifols S A Polígon Llevant   (Spain)

Author keywords

Alzheimer's disease; amyloid peptide; plasma albumin; plasma exchange; plasmapheresis

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; HUMAN ALBUMIN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SURFACE PLASMON RESONANCE;

EID: 84858112545     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111139     Document Type: Article

References (47)

1. Finlayson JS (1980) Immune globulins. Semin Thromb Hemost 6, 85-120.
2. Tullis JL (1977) Albumin. 2. Guidelines for clinical use. JAMA 237, 460-463.
3. Tullis JL (1977) Albumin. 1. Background and use. JAMA 237, 355-360.
4. Janeway C (1976) Human Serum Albumin: Historical Review. In: Proceedings of the Workshop on Albumin, Sgouris J, René A, Eds. Government Printing Office, DHEW Publication No. (NIH) 76-925, Washington, D.C., pp. 3-21.
5. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271, 32916-32922. (Pubitemid 27008725)
6. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351, 56-67.
7. Sastre M, Klockgether T, Heneka MT (2006) Contribution of inflammatory processes to Alzheimer's disease: Molecular mechanisms. Int J Dev Neurosci 24, 167-176. (Pubitemid 43294623)
8. Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, Naslund J, Richards G, Huber W, Dobeli H, Nordstedt C (1999) Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 274, 15990-15995.
9. Milojevic J, Raditsis A, Melacini G (2009) Human serum albumin inhibits Abeta fibrillization through a "monomer-competitor"mechanism. Biophys J 97, 2585-2594.
10. Peters T (1996) All about Albumin. Biochemistry, Genetics, and Medical Applications, Academic Press Inc., San Diego, CA.
11. Varshney A, Sen P, Ahmad E, Rehan M, Subbarao N, Khan RH (2010) Ligand binding strategies of human serum albumin: How can the cargo be utilized? Chirality 22, 77-87.
12. Sudlow G, Birkett DJ, Wade DN (1975) The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 11, 824-832.
13. Kragh-Hansen U (1991) Octanoate binding to the indoleand benzodiazepine-binding region of human serum albumin. Biochem J 273, 641-644.
14. Kragh-Hansen U, Chuang VT, Otagiri M (2002) Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 25, 695-704. (Pubitemid 40036701)
15. Arroyo V, Fernandez J (2011) Pathophysiological basis of albumin use in cirrhosis. J Hepatol 10(Suppl 1), S6-S14.
16. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochem Biophys Res Commun 268, 750-756. (Pubitemid 30150863)
17. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA (2003) Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463-470. (Pubitemid 39004272)
18. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A (2009) Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65, 927-934.
19. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98, 8850-8855. (Pubitemid 32678116)
20. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81, 229-236. (Pubitemid 34809348)
21. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002) Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267. (Pubitemid 34258840)
22. Kurz A, Perneczky R (2011) Amyloid clearance as a treatment target against Alzheimer's disease. J Alzheimers Dis 24, 61-73.
23. Bambauer R, Arnold A (1999) Plasmapheresis with a substitution solution of human serum protein (5%) versus plasmapheresis with a substitution solution of human albumin (5%) in patients suffering from autoimmune diseases. Artif Organs 23, 1079-1087. (Pubitemid 30021917)
24. Mazzi G, Raineri A, Zucco M, Passadore P, Pomes A, Orazi BM (1999) Plasma-exchange in chronic peripheral neurological disorders. Int J Artif Organs 22, 40-46. (Pubitemid 29104925)
25. Meca-Lallana JE, Rodriguez-Hilario H, Martinez-Vidal S, Saura-Lujan I, Carreton-Ballester A, Escribano-Soriano JB, Martin-Fernandez J, Genoves-Aleixandre A, Mateo-Bosch E, Fernandez-Barreiro A (2003) Plasmapheresis: Its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study. Rev Neurol 37, 917-926. (Pubitemid 37493764)
26. Boada M, Ortiz P, Anaya F, Hernandez I, Munoz. J, Nunez L, Olazaran J, Roca I, Cuberas G, Tarraga L, Buendia M, Pla RP, Ferrer I, Paez A (2009) Amyloid-targeted therapeutics in Alzheimer's disease: Use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect 22, 325-339.
27. Cohn EJ, Strong LE (1946) Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 68, 459-475.
28. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271, 22908-22914. (Pubitemid 26304742)
29. Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Naslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L (2000) Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med 6, 291-302.
30. Schaller J, Gerber S, Kämpfer U, Lejon S, Trachsel C (2008) Human Blood Plasma Proteins: Structure and Function, John Wiley & Sons, Ltd., Chichester, West Sussex, England.
31. Sarasa M, Pesini P, Monleón I, Pérez-Grijalba V, San-José I, Boada M, Martínez-Lage P, Tárraga L, Porcel-Carbonell J, Gutiérrez-Blanco A (2009) Evaluation of the beta-amyloid pool in blood by ELISA sandwich is meaningful and reliable. J Nutr Health Aging 13, P34.
32. Sarasa M, Pesini P, Boada M, Martínez-Lage P, Tárraga L, Monleón I, Pérez-Grijalba V, San-José I, Porcel-Carbonell J, Gutiérrez-Blanco A (2009) Differences in beta-amyloid pool in blood discriminate between amnesic mild cognitive impairment patients (AMCI) and healthy controls (HC). J Nutr Health Aging 13, P32.
33. Klammt S, Brinkmann B, Mitzner S, Munzert E, Loock J, Stange J, Emmrich J, Liebe S (2001) Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers. Z Gastroenterol 39(Suppl 2), 24-27.
34. Klammt S, Mitzner S, Stange J, Brinkmann B, Drewelow B, Emmrich J, Liebe S, Schmidt R (2007) Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur J Gastroenterol Hepatol 19, 257-263.
35. Smith EA, Corn RM (2003) Surface plasmon resonance imaging as a tool to monitor biomolecular interactions in an array based format. Appl Spectrosc 57, 320A-332A.
36. Johnsson B, Lofas S, Lindquist G (1991) Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem 198, 268-277.
37. Mayo CS, Hallock RB (1989) Immunoassay based on surface plasmon oscillations. J Immunol Methods 120, 105-114. (Pubitemid 19144202)
38. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 40 and 42 in Alzheimer disease. Arch Neurol 57, 100-105. (Pubitemid 30027637)
39. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S (2005) Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 62, 1539-1544. (Pubitemid 41434558)
40. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60, 958-964. (Pubitemid 36858355)
41. Lichtlen P, Mohajeri MH (2008) Antibody-based approaches in Alzheimer's research: Safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 104, 859-874. (Pubitemid 351143651)
42. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN (2005) Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 58, 147-150. (Pubitemid 40962471)
43. Milojevic J, Melacini G (2011) Stoichiometry and affinity of the human serum albumin-Alzheimer's Abeta peptide interactions. Biophys J 100, 183-192.
44. Rozga M, Kloniecki M, Jablonowska A, Dadlez M, Bal W (2007) The binding constant for amyloid Abeta40 peptide interaction with human serum albumin. Biochem Biophys Res Commun 364, 714-718. (Pubitemid 350026521)
45. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME (2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30, 1728-1736.
46. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Hoft C, Hemmer B, Moller HJ, Farlow M, Oertel WH, Sommer N, Du Y (2002) Human antibodies against amyloid beta peptide: A potential treatment for Alzheimer's disease. Ann Neurol 52, 253-256. (Pubitemid 34810613)
47. Costa M, Ortiz AM, Jorquera JI (2009) Binding of a beta-myloid 42 peptide to Human Albumin Grifols®. Alzheimers Dement 5(Suppl), P417.